Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The Anti-Fibrinolytic Drugs market in Bangladesh has been steadily growing over the past few years.
Customer preferences: Bangladesh has a high prevalence of bleeding disorders, such as hemophilia, which require the use of anti-fibrinolytic drugs to prevent excessive bleeding. As a result, there is a high demand for these drugs in the country.
Trends in the market: The market for anti-fibrinolytic drugs in Bangladesh has been growing due to an increase in the number of patients with bleeding disorders. Additionally, there has been an increase in the availability of these drugs in the country, which has made them more accessible to patients.
Local special circumstances: Bangladesh is a developing country with a large population, which means that there is a large potential market for anti-fibrinolytic drugs. However, there are challenges to accessing healthcare in the country, particularly in rural areas. This can make it difficult for patients to access the drugs they need.
Underlying macroeconomic factors: The healthcare sector in Bangladesh has been growing in recent years, with increased investment in healthcare infrastructure and services. This has helped to increase access to healthcare for many people in the country. Additionally, there has been a growing trend towards the use of generic drugs, which has helped to make anti-fibrinolytic drugs more affordable for patients.Overall, the Anti-Fibrinolytic Drugs market in Bangladesh is expected to continue to grow in the coming years, driven by an increase in the number of patients with bleeding disorders and an increase in access to healthcare. However, challenges related to healthcare access and affordability may limit the growth of the market in certain areas of the country.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights